249 related articles for article (PubMed ID: 3718142)
1. Hypereosinophilic syndrome associated with polycythemia vera.
Varon D; Wetzler M; Berrebi A
Arch Intern Med; 1986 Jul; 146(7):1440-1. PubMed ID: 3718142
[TBL] [Abstract][Full Text] [Related]
2. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic eosinophilic fasciitis: a case report.
Jacob SE; Lodha R; Cohen JJ; Romanelli P; Kirsner RS
Rheumatol Int; 2003 Sep; 23(5):262-4. PubMed ID: 12734672
[TBL] [Abstract][Full Text] [Related]
4. Acute leukemia in polycythemia vera.
Landaw SA
Semin Hematol; 1986 Apr; 23(2):156-65. PubMed ID: 3704667
[No Abstract] [Full Text] [Related]
5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
6. Improvement of fibrosis in a patient with chronic myeloproliferative disease.
Retter A; Radia DH; Harrison CN
Br J Haematol; 2007 Nov; 139(3):350. PubMed ID: 17910624
[No Abstract] [Full Text] [Related]
7. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
[TBL] [Abstract][Full Text] [Related]
9. Polycythaemia after myeloid metaplasia with fibrosis: an unusual sequence.
Gardais J; Suraniti S; Fressinaud P
Haematologica; 1992; 77(5):433-4. PubMed ID: 1483596
[TBL] [Abstract][Full Text] [Related]
10. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Barosi G; Birgegard G; Finazzi G; Griesshammer M; Harrison C; Hasselbalch H; Kiladijan JJ; Lengfelder E; Mesa R; Mc Mullin MF; Passamonti F; Reilly JT; Vannucchi AM; Barbui T
Br J Haematol; 2010 Mar; 148(6):961-3. PubMed ID: 19930182
[No Abstract] [Full Text] [Related]
11. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
Cacciola E; Cacciola RR; Guglielmo P; Stagno F; Giustolisi R
Haematologica; 1999 Aug; 84(8):755-6. PubMed ID: 10457418
[No Abstract] [Full Text] [Related]
13. The hypereosinophilic syndrome: dramatic response to therapeutic intervention.
Parrillo JE; Fauci AS; Wolff SM
Trans Assoc Am Physicians; 1977; 90():135-44. PubMed ID: 611659
[TBL] [Abstract][Full Text] [Related]
14. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
15. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
Fruchtman SM; Mack K; Kaplan ME; Peterson P; Berk PD; Wasserman LR
Semin Hematol; 1997 Jan; 34(1):17-23. PubMed ID: 9025158
[No Abstract] [Full Text] [Related]
16. [Amyloidosis and polycythemia vera (author's transl)].
Laudet J; Baumelou E; Chaignon M; Chapman A
Sem Hop; 1981 Dec 8-15; 57(45-46):1951-4. PubMed ID: 6275536
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis following polycythemia vera.
Tanaka M; Kanamori H; Yamaji S; Mishima A; Yamazaki E; Taguchi J; Aoba M; Fujisawa S; Mohri H; Ishigatsubo Y
Leuk Lymphoma; 2001 Jan; 40(3-4):437-40. PubMed ID: 11426569
[TBL] [Abstract][Full Text] [Related]
18. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
19. [Hypereosinophilic syndrome complicated by myelofibrosis].
Okabe S; Yahata N; Tauchi T; Otawa M; Iwase O; Toyama K; Ohyashiki K; Serizawa H; Ebihara Y
Rinsho Ketsueki; 1999 May; 40(5):420-2. PubMed ID: 10390892
[TBL] [Abstract][Full Text] [Related]
20. Extramedullary hematopoiesis and spinal cord compression complicating polycythemia rubra vera.
Rice GP; Assis LJ; Barr RM; Ebers GC
Ann Neurol; 1980 Jan; 7(1):81-4. PubMed ID: 7362209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
